Back to search results

THRIVE Intervention for Opioid Use Disorder and Harm Reduction

This study is testing a new program called THRIVE, which stands for "Teaching Health Resilience in a Hospital Setting." THRIVE is a peer-led program designed to help people with Opioid Use Disorder (OUD) reduce their risk of non-fatal overdoses or skin and soft tissue infections. If you join, you would either receive the THRIVE intervention, which includes one in-person session led by a peer and weekly text messages for 12 weeks, or enhanced usual care, which provides a handout with health education and local resources. Researchers want to see if the THRIVE intervention is more effective than usual care in lowering these risks over six months. You may be able to join if you are 18 or older and are admitted to certain UPMC hospitals or seen in their Emergency Departments.

Study design
This is an interventional study comparing the THRIVE intervention to enhanced usual care. It plans to enroll 390 participants.
What's involved
Participants receiving the THRIVE intervention will have one in-person session and receive weekly text messages for 12 weeks. The study measures outcomes up to 6 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for outcomes like non-fatal overdoses or skin and soft tissue infections from baseline to 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06843213

Teaching Health Resilience in a Hospital Setting: A Peer-led Intervention

Recruiting
NAAges 18+InterventionalPrevention
University of Pennsylvania
~390 participants
Updated 2026-02-27 on ClinicalTrials.gov
What's tested:Peer InterventionEnhanced Usual Care

At a glance

Recruiting sites
1 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Effectiveness of the THRIVE intervention compared to enhanced usual care (EUC) at lowering the incidence of non-fatal overdoses OR skin and soft tissue infections
Measured over Baseline to 6 months

Conditions

Opioid Use Disorder
Harm Reduction
Health Promotion

Explore related trials

Opioid Use Disorder

Where it's being run

3 sites across 1 states
Pennsylvania3

Study leadership

  • Jacqueline D Wilson, MD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania

Who to contact

Research Program Coordinator
[email protected]
412-679-9848
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants who are: a) admitted to University of Pittsburgh Medical Center (UPMC) Shadyside Hospital, UPMC Presbyterian-Montefiore Hospital, UPMC Mercy Hospital for inpatient or observation status, or b) seen in the Emergency Department setting at UPMC Presbyterian-Montefiore Hospital and UPMC Mercy Hospital.
Participants must have a current diagnosis of Opioid Use Disorder based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria.
Participants must be at least 18 years of age on day of admission.
Participants must be able to speak and read English.

Exclusion

Participants diagnosed with dementia and/or cognitive impairments.
Participants with acute psychiatric complications, such as schizophrenia with acute psychosis, acute mania, or suicidal ideation (which may impact the ability of a participant to consent and actively participate in treatment).
Participants who are pregnant or lactating at onset of study.
Participants who cannot read or speak English.

What this trial measures

  • Effectiveness of the THRIVE intervention compared to enhanced usual care (EUC) at lowering the incidence of non-fatal overdoses OR skin and soft tissue infectionsBaseline to 6 months

    Cumulative incidence of non-fatal overdose OR skin and soft tissue infection